← 產業報告目錄

Clinical Decision Support System (CDSS) Market by Type (Therapeutic, Diagnostic), Function (Medication, Treatment Planning, Risk Prediction), Indication (Primary Care, Onco, Cardio), End User (Hospital, ASC, Specialty) AI CDSS - Global Forecast to 2031

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2026-06-18頁數 408報告編號 HIT2237

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The clinical decision support systems (CDSS) market is expected to grow from USD 5.80 billion in 2026 to USD 10.15 billion by 2031, reflecting a CAGR of 11.8% over the forecast period. The increasing integration of CDSS with electronic health records (EHRs), computerized physician order entry (CPOE) platforms, and AI-enabled healthcare workflows is significantly accelerating market expansion across healthcare organizations. A growing emphasis on reducing medication errors, improving clinical efficiency, supporting evidence-based care, and enhancing patient safety is driving broader adoption of advanced CDSS platforms across hospitals and healthcare systems. Market growth is further supported by the rising implementation of artificial intelligence, predictive analytics, natural language processing (NLP), and cloud-connected healthcare technologies within clinical environments. In addition, increasing government focus on healthcare digitization, interoperability, and value-based care models is strengthening demand for interoperable and real-time clinical decision-support solutions. Expanding investments in healthcare IT modernization, connected healthcare ecosystems, and enterprise clinical intelligence platforms are expected to further support global CDSS market growth throughout the forecast period. “By end user, hospitals and health systems are expected to witness the highest growth during the forecast period.” By end user, the CDSS market is segmented into hospitals and integrated health systems, physician and specialty practices, ambulatory care centers, and other end users. Hospitals and integrated health systems represent the largest and fastest-growing end-user segment during the forecast period, driven by the increasing deployment of enterprise healthcare technologies and growing dependence on decision support systems across healthcare settings. Healthcare institutions are actively incorporating CDSS platforms into clinician workflows, medication management systems, diagnostic processes, and patient monitoring frameworks to improve treatment accuracy, reduce clinical variation, and strengthen patient safety outcomes. Rising hospital admission volumes, the increasing prevalence of complex diseases, and mounting pressure to improve operational efficiency are further supporting large-scale adoption of intelligent decision-support technologies across hospital networks. The widespread implementation of interoperable electronic health records (EHRs), cloud-enabled healthcare infrastructure, and AI-assisted clinical applications is also reinforcing the dominance of hospitals and health systems within the global CDSS landscape. In addition, healthcare providers are increasingly investing in predictive clinical intelligence, workflow automation, and real-time care coordination capabilities to support evidence-based care delivery and enterprise-wide healthcare optimization. By deployment model, the cloud-based CDSS segment is expected to witness the highest growth during the forecast period.” Based on deployment model, the CDSS market is segmented into cloud-based and on-premises CDSS. Cloud-based CDSS are projected to register the fastest growth during the forecast period. Rising adoption of scalable, interoperable, and accessible healthcare technologies is driving this demand across healthcare environments. Healthcare providers are increasingly shifting toward cloud-enabled clinical platforms to support real-time data exchange, enterprise-wide clinical coordination, AI-assisted decision-making, and seamless integration with EHRs and digital health ecosystems. The growing need for centralized data management, flexible infrastructure, lower upfront deployment costs, and faster software updates is further accelerating adoption of cloud-based CDSS solutions across hospitals, ambulatory care centers, and multi-site healthcare networks. In addition, the expanding use of telehealth, connected care solutions, remote patient monitoring systems, and AI-driven healthcare applications is strengthening demand for cloud-native decision-support technologies that enable continuous, data-driven patient care. Rising investments in healthcare cloud infrastructure are expected to further support strong segment growth throughout the forecast period. “Asia Pacific is estimated to register the highest CAGR during the forecast period.” The CDSS market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific CDSS market is projected to register the highest CAGR during the forecast period. Rapid adoption of digital healthcare infrastructure, increased implementation of health information systems based on interoperability standards, and the adoption of AI technologies are among the main drivers of this trend. Healthcare organizations in countries such as India, China, Japan, South Korea, Singapore, and Indonesia are actively promoting the modernization of clinical environments with cloud-powered health platforms, EHR systems, and AI-supported clinical solutions. Rising prevalence of chronic diseases, growing patient populations, and increasing demand for evidence-based clinical workflows are further accelerating the adoption of advanced decision-support technologies across hospitals and healthcare networks in the region. Governments are also strengthening national digital health initiatives and interoperability programs to support connected healthcare delivery and longitudinal patient data management. In May 2026, India’s Ayushman Bharat Digital Mission (ABDM) reported that more than 100 crore health records had been linked to ABHA accounts, reflecting substantial progress in interoperable healthcare infrastructure development and digital patient record integration. Increasing investments in healthcare IT modernization, scalable clinical intelligence platforms, and AI-enabled healthcare ecosystems are expected to continue driving strong CDSS market growth across Asia Pacific throughout the forecast period. In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the authentication and brand protection marketplace. • By Company Type: Tier 1 - 45%, Tier 2 - 35%, and Tier - 20% • By Designation: C-level Executives - 26%, Directors - 17%, and Others - 57% • By Region: North America – 40%, Europe – 20%, Asia Pacific – 30%, Latin America – 5%, and Middle East – 4% Wolters Kluwer (Netherlands), Epic Systems (US), Oracle Health (US), Optum (US), Merative (US), Veradigm LLC (US), and Athenahealth, Inc. (US) are key players in the CDSS market. The study includes an in-depth competitive analysis of these key players in the CDSS market, with their company profiles, recent developments, and key market strategies. Research Coverage The report analyzes the CDSS market. It estimates the market size and future growth potential across segments by component, type, technology, deployment, function, indication, end-user, and region. The report also provides a competitive analysis of key players in this market, including their company profiles, product offerings, recent developments, and key market strategies. Reasons to buy this report The report will provide market leaders and new entrants with the closest approximations of revenue figures for the CDSS market and its subsegments. It will help stakeholders understand the competitive landscape and gain insights to position their businesses more effectively and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides information on key market drivers, restraints, challenges, and opportunities. The report provides insights on the following pointers: • Analysis of key drivers (increasing adoption of Al-integrated and EHR-integrated CDSS, rising incidence of medication errors and clinical inefficiencies, growing government focus on digitization, interoperability, and value-based care), restraints (data security concerns, interoperability and integration complexity), opportunities (expansion of predictive analytics and generative Al, increasing adoption of cloud-based and interoperable healthcare ecosystems, high growth potential in emerging economies), and challenges (high implementation costs of enterprise CDSS platforms, shortage of AI-skilled healthcare professionals) influencing the growth of the CDSS market. • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the CDSS market • Market Development: Comprehensive information about lucrative markets, the report analyzes the CDSS market across varied regions • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the CDSS market • Competitive Assessment: In-depth assessment of market share, growth strategies, and service offerings of leading players such as Wolters Kluwer (Netherlands), Epic Systems (US), Oracle Health (US), Optum (US), Merative (US), Veradigm LLC (US), Athenahealth, Inc. (US), Elsevier (Netherlands), Zynx Health (US), Koninklijke Philips N.V. (Netherlands), and Medical Information Technology, Inc. (MEDITECH) (US), among others in the CDSS market.
目錄 Table of Contents
1 INTRODUCTION 34 1.1 STUDY OBJECTIVES 34 1.2 MARKET DEFINITION 34 1.3 MARKET SCOPE 35 1.3.1 MARKETS COVERED 35 1.3.2 INCLUSIONS AND EXCLUSIONS 36 1.3.3 YEARS CONSIDERED 37 1.4 CURRENCY CONSIDERED 37 1.5 STAKEHOLDERS 38 1.6 SUMMARY OF CHANGES 38 2 EXECUTIVE SUMMARY 39 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 39 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 41 2.3 DISRUPTIVE TRENDS SHAPING MARKET 42 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 43 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 44 3 PREMIUM INSIGHTS 45 3.1 CLINICAL DECISION SUPPORT SYSTEM MARKET OVERVIEW 45 3.2 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT AND COUNTRY 46 3.3 CLINICAL DECISION SUPPORT SYSTEMS MARKET: REGIONAL GROWTH OPPORTUNITIES 46 4 MARKET OVERVIEW 47 4.1 INTRODUCTION 47 4.2 MARKET DYNAMICS 48 4.2.1 DRIVERS 48 4.2.1.1 Growing government focus on digitization, interoperability, and value-based care 48 4.2.1.2 Increasing adoption of Al-integrated and EHR-integrated CDSS 50 4.2.1.3 Rising incidence of medication errors and clinical inefficiencies 50 4.2.2 RESTRAINTS 51 4.2.2.1 Data security concerns 51 4.2.2.2 Interoperability and integration complexity 51 4.2.3 OPPORTUNITIES 52 4.2.3.1 Expansion of predictive analytics and Generative Al 52 4.2.3.2 High growth potential in emerging economies 52 4.2.3.3 Increasing adoption of cloud-based and interoperable healthcare ecosystems 53 4.2.4 CHALLENGES 54 4.2.4.1 High implementation costs of enterprise CDSS platforms 54 4.2.4.2 Shortage of Al-skilled healthcare professionals 54 4.3 UNMET NEEDS AND WHITE SPACES 55 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 55 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 56 5 INDUSTRY TRENDS 57 5.1 PORTER'S FIVE FORCES ANALYSIS 57 5.1.1 THREAT OF NEW ENTRANTS 58 5.1.2 THREAT OF SUBSTITUTES 58 5.1.3 BARGAINING POWER OF SUPPLIERS 58 5.1.4 BARGAINING POWER OF BUYERS 58 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 59 5.2 MACROECONOMIC INDICATORS 59 5.2.1 INTRODUCTION 59 5.2.2 GDP TRENDS AND FORECAST 59 5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 59 5.3 VALUE CHAIN ANALYSIS 60 5.3.1 RESEARCH & PRODUCT DEVELOPMENT 61 5.3.2 DATA & KNOWLEDGE ASSETS 61 5.3.3 SOFTWARE & PLATFORM INFRASTRUCTURE 62 5.3.4 CLOUD SERVICE PROVIDERS 62 5.3.5 MARKETING & SALES 62 5.3.6 POST-SALES SERVICES 62 5.4 ECOSYSTEM ANALYSIS 62 5.5 PRICING ANALYSIS 65 5.5.1 INDICATIVE PRICE FOR CDSS MARKET, BY PRODUCT (2025) 66 5.5.2 INDICATIVE PRICE FOR CDSS MAREKT, BY REGION (2025) 67 5.6 KEY CONFERENCES AND EVENTS 67 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 69 5.8 INVESTMENTS AND FUNDING 69 5.9 CASE STUDY ANALYSIS 70 5.9.1 IMPROVING PATIENT OUTCOMES 70 5.9.2 IMPROVING CLINICAL DECISION-MAKING 71 5.9.3 ENHANCING MEDICATION SAFETY 71 5.9.4 INCREASING CLINICAL EFFICIENCY 72 5.10 IMPACT OF 2025 US TARIFF—OVERVIEW 72 5.10.1 INTRODUCTION 72 5.10.2 KEY TARIFF RATES 73 5.10.3 PRICE IMPACT ANALYSIS 73 5.10.4 IMPACT ON COUNTRY/REGION 74 5.10.4.1 The US 74 5.10.4.2 Europe 74 5.10.4.3 APAC 74 5.10.5 IMPACT ON END USE INDUSTRIES 75 6 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTION 77 6.1 KEY EMERGING TECHNOLOGIES 77 6.1.1 DEEP LEARNING & PREDICTIVE CLINICAL ANALYTICS TECHNOLOGIES 77 6.1.2 NATURAL LANGUAGE PROCESSING (NLP) & GENERATIVE AI TECHNOLOGIES 77 6.1.3 REAL-TIME INTELLIGENCE & WORKFLOW-ORIENTED AI TECHNOLOGIES 78 6.2 COMPLEMENTARY TECHNOLOGIES 78 6.2.1 ELECTRONIC HEALTH RECORDS (EHR), FHIR & HEALTHCARE INTEROPERABILITY TECHNOLOGIES 78 6.2.2 CLOUD-BASED, EDGE & HYBRID CLINICAL COMPUTING TECHNOLOGIES 79 6.3 ADJACENT TECHNOLOGIES 79 6.3.1 AMBIENT CLINICAL OPERATIONAL & DOCUMENTATION TECHNOLOGIES 79 6.3.2 DIAGNOSTIC AND IMAGING TECHNOLOGIES 79 6.4 TECHNOLOGY/PRODUCT ROADMAP 80 6.5 PATENT ANALYSIS 81 6.5.1 PATENT PUBLICATION TRENDS FOR CLINICAL DECISION SUPPORT SYSTEMS 81 6.5.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 82 6.5.3 LIST OF SOME PATENTS/PATENT APPLICATIONS FOR CDSS 85 6.6 FUTURE APPLICATIONS 86 6.6.1 AI-ASSISTED PERSONALIZED CLINICAL DECISION SUPPORT 87 6.6.2 AMBIENT CLINICAL INTELLIGENCE & AUTONOMOUS WORKFLOW ASSISTANCE 87 6.6.3 PREDICTIVE POPULATION HEALTH & CONTINUOUS CARE MANAGEMENT 87 6.7 IMPACT OF AI/GEN AI ON CDSS MARKET 88 6.7.1 INTRODUCTION 88 6.7.2 MARKET POTENTIAL OF AI/GEN AI IN CDSS MARKET 89 6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 90 6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 91 6.7.4.1 Electronic Health Records (EHR) & Healthcare Interoperability 91 6.7.4.2 Remote Patient Monitoring (RPM), Telehealth & Digital Care 91 6.7.4.3 Population Health Management (PHM) 92 6.7.5 USER READINESS AND IMPACT ASSESSMENT 92 6.7.5.1 User Readiness 92 6.7.5.1.1 User A: Hospitals & Integrated Health Systems 92 6.7.5.1.2 User B: Ambulatory Care Centers & Physician Practices 92 6.7.5.2 Impact Assessment 93 6.7.5.2.1 User A: Hospitals & Integrated Health Systems 93 6.7.5.2.1.1 IMPLEMENTATION 93 6.7.5.2.1.2 IMPACT 93 6.7.5.2.2 User B: Ambulatory Care Centers & Physician Practices 93 6.7.5.2.2.1 IMPLEMENTATION 93 6.7.5.2.2.1.1 IMPACT 94 7 REGULATORY LANDSCAPE 95 7.1 REGIONAL REGULATIONS AND COMPLIANCE 95 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95 7.1.2 REGULATORY FRAMEWORK 101 7.1.2.1 North America 101 7.1.2.2 Europe 102 7.1.2.3 Asia Pacific 102 7.1.2.4 Latin America 103 7.1.2.5 Middle East & Africa 104 7.1.3 INDUSTRY STANDARDS 104 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 106 8.1 INTRODUCTION 106 8.2 DECISION-MAKING PROCESS 106 8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 106 8.4 KEY STAKEHOLDERS IN BUYING PROCESS 107 8.4.1 KEY STAKEHOLDERS IN BUYING PROCESS 107 8.4.2 BUYING CRITERIA 108 8.5 ADOPTION BARRIERS & INTERNAL CHALLENGES 109 8.6 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 109 8.6.1 UNMET NEEDS 110 8.6.2 END-USER EXPECTATIONS 111 8.7 MARKET PROFITABILITY 113 9 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT 114 9.1 INTRODUCTION 115 9.2 SOFTWARE 115 9.2.1 INTEGRATED CDSS 116 9.2.1.1 EHR integration and real-time clinical decision support to drive market growth 116 9.2.2 STANDALONE CDSS 117 9.2.2.1 Specialized clinical decision support applications to support market growth 117 9.3 SERVICES 118 9.3.1 SPECIALIZED APPLICATIONS TO SUPPORT RECURRING REQUIREMENT TO DRIVE MARKET 118 10 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE 120 10.1 INTRODUCTION 121 10.2 THERAPEUTIC CDSS 121 10.2.1 INCREASING DEMAND FOR EVIDENCE-BASED TREATMENT DECISION SUPPORT TO DRIVE MARKET GROWTH 121 10.3 DIAGNOSTIC CDSS 122 10.3.1 INCREASING DEMAND FOR ACCURATE AND TIMELY DIAGNOSTIC DECISION SUPPORT TO BOOST MARKET 122 11 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY 124 11.1 INTRODUCTION 125 11.2 KNOWLEDGE-BASED CDSS 125 11.2.1 DEPLOYS CONDITIONAL LOGIC FOR DECISION-MAKING AND PROBLEM ANALYSIS 125 11.3 NON-KNOWLEDGE-BASED CDSS 127 11.3.1 ADVANCEMENTS IN AI AND PREDICTIVE ANALYTICS TO DRIVE MARKET EXPANSION 127 12 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL 129 12.1 INTRODUCTION 130 12.2 CLOUD-BASED 130 12.2.1 SCALABILITY, INTEROPERABILITY, AND AI-ENABLED WORKFLOWS BOOST GROWTH 130 12.3 ON-PREMISES 131 12.3.1 GREATER DATA CONTROL AND CUSTOMIZATION TO SUPPORT CONTINUED ADOPTION 131 13 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION 133 13.1 INTRODUCTION 134 13.2 MEDICATION MANAGEMENT SUPPORT 134 13.2.1 INCREASING FOCUS ON MEDICATION SAFETY AND ERROR REDUCTION TO DRIVE MARKET GROWTH 134 13.3 DIAGNOSTIC DECISION SUPPORT 135 13.3.1 GROWING DEMAND FOR ACCURATE AND TIMELY DIAGNOSTIC INSIGHTS TO DRIVE MARKET GROWTH 135 13.4 TREATMENT PLANNING & CLINICAL PATHWAY SUPPORT 136 13.4.1 INCREASING ADOPTION OF EVIDENCE-BASED CARE PATHWAYS TO SUPPORT MARKET EXPANSION 136 13.5 RISK PREDICTION & PREVENTIVE CARE 137 13.5.1 EXPANDING USE OF PREDICTIVE ANALYTICS TO DRIVE MARKET GROWTH 137 13.6 OTHER FUNCTIONS 138 14 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION 139 14.1 INTRODUCTION 140 14.2 PRIMARY CARE & GENERAL MEDICINE 140 14.2.1 INCREASING DEMAND FOR EVIDENCE-BASED DECISION SUPPORT IN HIGH-VOLUME CARE SETTINGS TO DRIVE MARKET GROWTH 140 14.3 ONCOLOGY 141 14.3.1 INCREASING COMPLEXITY OF CANCER CARE SUPPORTS MARKET EXPANSION 141 14.4 CARDIOLOGY 142 14.4.1 GROWING DEMAND FOR CARDIOVASCULAR RISK STRATIFICATION AND CLINICAL DECISION SUPPORT 142 14.5 CRITICAL CARE & EMERGENCY MEDICINE 143 14.5.1 REAL-TIME CLINICAL DECISION SUPPORT TO IMPROVE ACUTE CARE OUTCOMES 143 14.6 NEUROLOGY 144 14.6.1 ADVANCEMENTS IN AI-ENABLED NEUROLOGICAL DECISION SUPPORT TO DRIVE MARKET GROWTH 144 14.7 OTHERS 145 14.7.1 ABILITY TO ENABLE OPTIMAL DECISION-MAKING WITH MINIMAL ERRORS TO DRIVE MARKET 145 15 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER 146 15.1 INTRODUCTION 147 15.2 HOSPITALS & HEALTH SYSTEMS 147 15.2.1 INCREASING ADOPTION OF ENTERPRISE-WIDE CLINICAL DECISION SUPPORT TO DRIVE MARKET GROWTH 147 15.3 PHYSICIAN & SPECIALTY PRACTICES 148 15.3.1 GROWING NEED FOR EFFICIENT CLINICAL DECISION-MAKING TO SUPPORT MARKET EXPANSION 148 15.4 AMBULATORY CARE CENTERS 149 15.4.1 EXPANDING OUTPATIENT CARE DELIVERY TO ACCELERATE CDSS ADOPTION 149 15.5 OTHER END USERS 150 15.5.1 EXPANDING UTILIZATION OF CLINICAL DECISION SUPPORT ACROSS DIVERSE HEALTHCARE SETTINGS 150 16 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY REGION 151 16.1 INTRODUCTION 152 16.2 NORTH AMERICA 152 16.2.1 NORTH AMERICA: MACROECONOMIC IMPACT 152 16.2.2 US 157 16.2.2.1 Expansion of AI-enabled value-based care to accelerate CDSS adoption 157 16.2.3 CANADA 161 16.2.3.1 Accelerating digital health interoperability to strengthen CDSS adoption 161 16.3 EUROPE 164 16.3.1 EUROPE: MACROECONOMIC IMPACT 165 16.3.2 GERMANY 168 16.3.2.1 Favorable government support for digital health and electronic patient records to propel market 168 16.3.3 UK 172 16.3.3.1 NHS digital transformation and interoperable healthcare infrastructure drive market 172 16.3.4 FRANCE 175 16.3.4.1 Robust interoperability for EHR systems to drive market 175 16.3.5 ITALY 179 16.3.5.1 Expansion of interoperable electronic health records to accelerate CDSS adoption 179 16.3.6 SPAIN 182 16.3.6.1 Growing adoption of interoperable electronic health records to support market growth 182 16.3.7 REST OF EUROPE 185 16.4 ASIA PACIFIC 188 16.4.1 ASIA PACIFIC: MACROECONOMIC IMPACT 189 16.4.2 JAPAN 193 16.4.2.1 Medical DX initiatives and standardized electronic medical records to propel market 193 16.4.3 CHINA 196 16.4.3.1 Government-led digital hospital transformation and EMR maturity to drive market 196 16.4.4 INDIA 199 16.4.4.1 Expansion of Ayushman Bharat Digital Mission to accelerate CDSS adoption 199 16.4.5 AUSTRALIA 203 16.4.5.1 Nationwide adoption of My Health Record to accelerate CDSS deployment 203 16.4.6 SOUTH KOREA 206 16.4.6.1 Government-led digital health regulations and AI adoption to drive market 206 16.4.7 REST OF ASIA PACIFIC 210 16.5 LATIN AMERICA 213 16.5.1 LATIN AMERICA: MACROECONOMIC IMPACT 214 16.5.2 BRAZIL 217 16.5.2.1 Strengthening national health information exchange to accelerate CDSS adoption 217 16.5.3 MEXICO 220 16.5.3.1 Digital transformation initiatives in healthcare to support CDSS adoption 220 16.5.4 REST OF LATIN AMERICA 223 16.5.4.1 Growing healthcare digitalization to support CDSS adoption 223 16.6 MIDDLE EAST & AFRICA 226 16.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC IMPACT 227 16.6.2 GCC COUNTRIES 230 16.6.2.1 Rising demand to digitize healthcare IT to propel market 230 16.6.3 SAUDI ARABIA 234 16.6.3.1 National digital health transformation to accelerate CDSS adoption 234 16.6.4 UAE 237 16.6.4.1 Expansion of nationwide health information exchange to drive market 237 16.6.5 OTHER GCC COUNTRIES 240 16.6.5.1 Increasing digital health investments to support CDSS adoption 240 16.6.6 SOUTH AFRICA 243 16.6.6.1 Focus on modernizing healthcare systems to drive market 243 16.6.7 REST OF MIDDLE EAST & AFRICA 246 16.6.7.1 Growing government-led digital health initiatives to support market growth 246 17 COMPETITIVE LANDSCAPE 250 17.1 OVERVIEW 250 17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023–2026 250 17.3 REVENUE ANALYSIS, 2021-2025 253 17.4 MARKET SHARE ANALYSIS, 2021–2025 254 17.5 BRAND COMPARISON 257 17.6 COMPANY VALUATION AND FINANCIAL METRICS 258 17.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 259 17.7.1 STARS 259 17.7.2 EMERGING LEADERS 259 17.7.3 PERVASIVE PLAYERS 259 17.7.4 PARTICIPANTS 259 17.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 261 17.7.5.1 Company footprint 261 17.7.5.2 Region footprint 262 17.7.5.3 Component footprint 263 17.7.5.4 Type footprint 264 17.7.5.5 Technology footprint 265 17.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 266 17.8.1 PROGRESSIVE COMPANIES 266 17.8.2 RESPONSIVE COMPANIES 266 17.8.3 DYNAMIC COMPANIES 266 17.8.4 STARTING BLOCKS 266 17.8.4.1 COMPETITIVE BENCHMARKING STARTUPS/SMES, 2025 267 17.9 COMPETITIVE SCENARIO 269 17.9.1 DEALS 271 17.9.2 OTHER DEVELOPMENTS 275 18 COMPANY PROFILES 277 18.1 KEY PLAYERS 277 18.1.1 WOLTERS KLUWER N.V. 277 18.1.1.1 Business overview 277 18.1.1.2 Product/solutions/services s offered 279 18.1.1.3 Recent developments 280 18.1.1.3.1 Product launches & upgrades 280 18.1.1.3.2 Deals 281 18.1.1.3.3 Other developments 284 18.1.1.4 MnM view 284 18.1.1.4.1 Key strengths 284 18.1.1.4.2 Strategic choices 285 18.1.1.4.3 Weaknesses and competitive threats 285 18.1.2 EPIC SYSTEMS CORPORATION 286 18.1.2.1 Business overview 286 18.1.2.2 Products/solutions/services offered 287 18.1.2.3 Recent developments 289 18.1.2.3.1 Product launches & upgrades 289 18.1.2.3.2 Deals 290 18.1.2.3.3 Other developments 291 18.1.2.4 MnM view 291 18.1.2.4.1 Key strengths 291 18.1.2.4.2 Strategic choices 292 18.1.2.4.3 Weaknesses and competitive threats 292 18.1.3 ORACLE 293 18.1.3.1 Business overview 293 18.1.3.2 Products/solutions/services offered 294 18.1.3.3 Recent developments 296 18.1.3.3.1 Product launches & upgrades 296 18.1.3.3.2 Deals 297 18.1.3.4 MnM view 299 18.1.3.4.1 Key strengths 299 18.1.3.4.2 Strategic choices 299 18.1.3.4.3 Weaknesses and competitive threats 299 18.1.4 MERATIVE 300 18.1.4.1 Business overview 300 18.1.4.2 Products/solutions/services offered 300 18.1.4.3 Recent developments 301 18.1.4.3.1 Product launches & upgrades 301 18.1.4.3.2 Deals 301 18.1.4.3.3 Other developments 302 18.1.4.4 MnM view 302 18.1.4.4.1 Key strengths 302 18.1.4.4.2 Strategic choices 303 18.1.4.4.3 Weaknesses and competitive threats 303 18.1.5 VERADIGM LLC 304 18.1.5.1 Business overview 304 18.1.5.2 Products/solutions/services offered 305 18.1.5.3 Recent developments 307 18.1.5.3.1 Product launches & upgrades 307 18.1.5.3.2 Deals 308 18.1.5.3.3 Other developments 309 18.1.5.4 MnM view 309 18.1.5.4.1 Key strengths 309 18.1.5.4.2 Strategic choices 310 18.1.5.4.3 Weaknesses and competitive threats 310 18.1.6 OPTUM, INC. (UNITEDHEALTH GROUP) 311 18.1.6.1 Business overview 311 18.1.6.2 Products/solutions/services offered 312 18.1.6.3 Recent developments 313 18.1.6.3.1 Product launches & upgrades 313 18.1.6.3.2 Deals 314 18.1.7 ATHENAHEALTH 315 18.1.7.1 Business overview 315 18.1.7.2 Products/solutions/services offered 316 18.1.7.3 Recent developments 316 18.1.7.3.1 Product launches & upgrades 316 18.1.7.3.2 Deals 317 18.1.8 ELSEVIER (DIVISION OF RELX GROUP) 319 18.1.8.1 Business overview 319 18.1.8.2 Products/solutions/services offered 320 18.1.8.3 Recent developments 322 18.1.8.3.1 Product launches & upgrades 322 18.1.8.3.2 Deals 323 18.1.9 ZYNX HEALTH, INC. 324 18.1.9.1 Business overview 324 18.1.9.2 Products/solutions/services offered 325 18.1.9.3 Recent developments 326 18.1.9.3.1 Product launches & upgrades 326 18.1.9.3.2 Deals 326 18.1.9.3.3 Other developments 326 18.1.10 KONINKLIJKE PHILIPS N.V. 327 18.1.10.1 Business overview 327 18.1.10.2 Products/solutions/services offered 328 18.1.10.3 Recent developments 330 18.1.10.3.1 Product launches & upgrades 330 18.1.10.3.2 Deals 331 18.1.11 MEDICAL INFORMATION TECHNOLOGY, INC. 333 18.1.11.1 Business overview 333 18.1.11.2 Products/solutions/services offered 334 18.1.11.3 Recent developments 335 18.1.11.3.1 Product launches & upgrades 335 18.1.11.3.2 Deals 336 18.1.11.3.3 Other developments 337 18.1.12 NEXTGEN HEALTHCARE, INC. 338 18.1.12.1 Business overview 338 18.1.12.2 Products/solutions/services offered 340 18.1.12.3 Recent developments 341 18.1.12.3.1 Product launches & upgrades 341 18.1.12.3.2 Deals 342 18.1.13 CUREMD HEALTHCARE 345 18.1.13.1 Business overview 345 18.1.13.2 Products/solutions/services offered 346 18.1.13.3 Recent developments 347 18.1.13.3.1 Product Launches & upgrades 347 18.1.13.3.2 Deals 348 18.1.13.3.3 Other developments 348 18.1.14 SIEMENS HEALTHINEERS AG 349 18.1.14.1 Business overview 349 18.1.14.2 Products/solutions/services offered 350 18.1.14.3 Recent developments 352 18.1.14.3.1 Products launches & upgrades 352 18.1.14.3.2 Deals 352 18.1.15 EBSCO INFORMATION SERVICES 354 18.1.15.1 Business overview 354 18.1.15.2 Products/solutions/services offered 355 18.1.15.3 Recent developments 356 18.1.15.3.1 Product launches & upgrades 356 18.1.15.3.2 Deals 357 18.1.16 GE HEALTHCARE 358 18.1.16.1 Business overview 358 18.1.16.2 Products/solutions/services offered 360 18.1.16.3 Recent developments 361 18.1.16.3.1 Product launches & upgrades 361 18.1.16.3.2 Deals 362 18.1.16.3.3 Other developments 365 18.1.17 ECLINICALWORKS, LLC 366 18.1.17.1 Business overview 366 18.1.17.2 Products/Solutions/Services Offered 367 18.1.17.3 Recent developments 367 18.1.17.3.1 Product launches & upgrades 367 18.1.17.4 Recent developments 368 18.1.17.4.1 Deals 368 18.1.18 THE MEDICAL ALGORITHMS COMPANY LIMITED 370 18.1.18.1 Business overview 370 18.1.18.2 Products/solutions/services offered 371 18.1.19 CARECLOUD, INC. 372 18.1.19.1 Business overview 372 18.1.19.2 Products/solutions/services offered 373 18.1.19.3 Recent developments 374 18.1.19.3.1 Product launches & upgrades 374 18.1.19.3.2 Deals 375 18.1.20 VISUALDX 377 18.1.20.1 Business overview 377 18.1.20.2 Products/solutions/services offered 378 18.1.20.3 Recent developments 379 18.1.20.3.1 Deals 379 18.2 OTHER PLAYERS 380 18.2.1 MACUSOFT 380 18.2.2 HERA-MI 380 18.2.3 COHESIC INC. 381 18.2.4 MEDEA MIND 381 18.2.5 GLASS HEALTH 382 18.2.6 MEDECIPHER 382 19 RESEARCH METHODOLOGY 383 19.1 RESEARCH APPROACH 383 19.1.1 SECONDARY RESEARCH 384 19.1.1.1 Key data from secondary sources 385 19.1.2 PRIMARY RESEARCH 385 19.1.2.1 Key data from primary sources 387 19.1.2.2 Insights from primary experts 388 19.2 RESEARCH METHODOLOGY 389 19.3 MARKET SIZE ESTIMATION 391 19.4 MARKET BREAKDOWN DATA TRIANGULATION 396 19.5 MARKET SHARE ESTIMATION 397 19.6 STUDY ASSUMPTIONS 397 19.7 LIMITATIONS 398 19.7.1 SCOPE-RELATED LIMITATIONS 398 19.7.2 METHODOLOGY-RELATED LIMITATIONS 398 19.8 RISK ASSESSMENT 398 20 APPENDIX 399 20.1 DISCUSSION GUIDE 399 20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 404 20.3 CUSTOMIZATION OPTIONS 406 20.4 RELATED REPORTS 406 20.5 AUTHOR DETAILS 407
圖表清單 List of Tables & Figures
TABLE 1 EXCHANGE RATES FOR CONVERSION TO USD 37 TABLE 2 CLINICAL DECISION SUPPORT SYSTEMS MARKET: PORTER’S FIVE FORCES ANALYSIS 58 TABLE 3 CDSS MARKET: ROLE IN ECOSYSTEM 65 TABLE 4 INDICATIVE PRICE FOR CDSS MAREKT, BY REGION (2025) 67 TABLE 5 CLINICAL DECISION SUPPORT SYSTEMS: DETAILED LIST OF CONFERENCES AND EVENTS (2026–2027) 67 TABLE 6 CASE 1: RISING FOCUS ON IMPROVING PATIENT SAFETY 70 TABLE 7 CASE 2: IMPROVING CLINICAL DECISION-MAKING THROUGH PROVINCE-WIDE HEALTH INFORMATION TRANSFORMATION 71 TABLE 8 CASE 3: ENHANCING MEDICATION SAFETY THROUGH PERSONALIZED DECISION SUPPORT 71 TABLE 9 CASE 4: IMPROVING CLINICAL EFFICIENCY THROUGH ENTERPRISE EHR MODERNIZATION 72 TABLE 10 US ADJUSTED RECIPROCAL TARIFF RATES 73 TABLE 11 TOP APPLICANT COUNTRIES FOR CDSS PATENTS 83 TABLE 12 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96 TABLE 13 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97 TABLE 14 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98 TABLE 15 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99 TABLE 16 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 100 TABLE 17 REGULATORY SCENARIO OF NORTH AMERICA 101 TABLE 18 REGULATORY SCENARIO OF EUROPE 102 TABLE 19 REGULATORY SCENARIO OF ASIA PACIFIC 102 TABLE 20 REGULATORY SCENARIO OF LATIN AMERICA 103 TABLE 21 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA 104 TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%) 108 TABLE 23 BUYING CRITERIA FOR COMPONENTS, BY RANK 109 TABLE 24 UNMET NEEDS IN CDSS MARKET 110 TABLE 25 END-USER EXPECTATIONS IN CDSS MARKET 112 TABLE 26 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 115 TABLE 27 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR SOFTWARE, BY REGION, 2024–2031 (USD MILLION) 115 TABLE 28 INTEGRATED CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 117 TABLE 29 STANDALONE CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 118 TABLE 30 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR SERVICES, BY REGION, 2024–2031 (USD MILLION) 119 TABLE 31 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 121 TABLE 32 THERAPEUTIC CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 122 TABLE 33 DIAGNOSTIC CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 123 TABLE 34 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 125 TABLE 35 KNOWLEDGE-BASED CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 126 TABLE 36 NON-KNOWLEDGE-BASED CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 128 TABLE 37 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 130 TABLE 38 CLOUD-BASED CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 131 TABLE 39 ON-PREMISE CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 132 TABLE 40 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 134 TABLE 41 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR MEDICATION MANAGEMENT SUPPORT, BY REGION, 2024–2031 (USD MILLION) 135 TABLE 42 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR DIAGNOSTIC DECISION SUPPORT, BY REGION, 2024–2031 (USD MILLION) 136 TABLE 43 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR TREATMENT PLANNING & CLINICAL PATHWAY SUPPORT, BY REGION, 2024–2031 (USD MILLION) 137 TABLE 44 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR RISK PREDICTION & PREVENTIVE CARE, BY REGION, 2024–2031 (USD MILLION) 137 TABLE 45 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR OTHER FUNCTIONS, BY REGION, 2024–2031 (USD MILLION) 138 TABLE 46 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 140 TABLE 47 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR PRIMARY CARE & GENERAL MEDICINE, BY REGION, 2024–2031 (USD MILLION) 141 TABLE 48 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION) 142 TABLE 49 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR CARDIOLOGY, BY REGION, 2024–2031 (USD MILLION) 143 TABLE 50 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR CRITICAL CARE & EMERGENCY MEDICINE, BY REGION, 2024–2031 (USD MILLION) 143 TABLE 51 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR NEUROLOGY, BY REGION, 2024–2031 (USD MILLION) 144 TABLE 52 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2031 (USD MILLION) 145 TABLE 53 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 147 TABLE 54 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR HOSPITALS & HEALTH SYSTEMS, BY REGION, 2024–2031 (USD MILLION) 148 TABLE 55 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR PHYSICIAN & SPECIALTY PRACTICES, BY REGION, 2024–2031 (USD MILLION) 149 TABLE 56 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR AMBULATORY CARE CENTERS, BY REGION, 2024–2031 (USD MILLION) 150 TABLE 57 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 150 TABLE 58 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 152 TABLE 59 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 60 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 154 TABLE 61 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 154 TABLE 62 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 155 TABLE 63 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 155 TABLE 64 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 155 TABLE 65 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 156 TABLE 66 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 156 TABLE 67 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 157 TABLE 68 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 158 TABLE 69 US: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 158 TABLE 70 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 159 TABLE 71 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 159 TABLE 72 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 159 TABLE 73 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 160 TABLE 74 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 160 TABLE 75 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 161 TABLE 76 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 162 TABLE 77 CANADA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 162 TABLE 78 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 162 TABLE 79 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 163 TABLE 80 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 163 TABLE 81 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 163 TABLE 82 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 164 TABLE 83 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 164 TABLE 84 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 85 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 166 TABLE 86 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 166 TABLE 87 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 166 TABLE 88 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 167 TABLE 89 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 167 TABLE 90 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 167 TABLE 91 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 168 TABLE 92 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 168 TABLE 93 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 169 TABLE 94 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 169 TABLE 95 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 170 TABLE 96 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 170 TABLE 97 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 170 TABLE 98 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 171 TABLE 99 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 171 TABLE 100 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 172 TABLE 101 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 173 TABLE 102 UK: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 173 TABLE 103 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 173 TABLE 104 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 174 TABLE 105 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 174 TABLE 106 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 174 TABLE 107 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 175 TABLE 108 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 175 TABLE 109 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 176 TABLE 110 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 176 TABLE 111 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 177 TABLE 112 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 177 TABLE 113 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 177 TABLE 114 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 178 TABLE 115 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 178 TABLE 116 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 179 TABLE 117 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 180 TABLE 118 ITALY: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 180 TABLE 119 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 180 TABLE 120 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 181 TABLE 121 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 181 TABLE 122 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 181 TABLE 123 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 182 TABLE 124 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 182 TABLE 125 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 183 TABLE 126 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 183 TABLE 127 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 183 TABLE 128 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 184 TABLE 129 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 184 TABLE 130 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 184 TABLE 131 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 185 TABLE 132 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 185 TABLE 133 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 186 TABLE 134 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 186 TABLE 135 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 186 TABLE 136 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 187 TABLE 137 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 187 TABLE 138 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 187 TABLE 139 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 188 TABLE 140 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 188 TABLE 141 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 142 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 191 TABLE 143 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 191 TABLE 144 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 191 TABLE 145 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 192 TABLE 146 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 192 TABLE 147 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION LEVEL, 2024–2031 (USD MILLION) 192 TABLE 148 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 193 TABLE 149 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 193 TABLE 150 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 194 TABLE 151 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 194 TABLE 152 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 194 TABLE 153 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 195 TABLE 154 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 195 TABLE 155 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 195 TABLE 156 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 196 TABLE 157 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 196 TABLE 158 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 197 TABLE 159 CHINA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 197 TABLE 160 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 197 TABLE 161 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 198 TABLE 162 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 198 TABLE 163 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 198 TABLE 164 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 199 TABLE 165 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 199 TABLE 166 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 200 TABLE 167 INDIA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 200 TABLE 168 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 201 TABLE 169 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 201 TABLE 170 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 201 TABLE 171 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 202 TABLE 172 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 202 TABLE 173 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 203 TABLE 174 AUSTRALIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 204 TABLE 175 AUSTRALIA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 176 AUSTRALIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 177 AUSTRALIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 205 TABLE 178 AUSTRALIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 205 TABLE 179 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 205 TABLE 180 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 206 TABLE 181 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 206 TABLE 182 SOUTH KOREA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 207 TABLE 183 SOUTH KOREA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 207 TABLE 184 SOUTH KOREA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 185 SOUTH KOREA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 208 TABLE 186 SOUTH KOREA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 208 TABLE 187 SOUTH KOREA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 209 TABLE 188 SOUTH KOREA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 209 TABLE 189 SOUTH KOREA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 210 TABLE 190 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 211 TABLE 191 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 211 TABLE 192 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 211 TABLE 193 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 212 TABLE 194 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 212 TABLE 195 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 212 TABLE 196 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 213 TABLE 197 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 213 TABLE 198 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 214 TABLE 199 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 214 TABLE 200 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 201 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 202 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 215 TABLE 203 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 216 TABLE 204 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 216 TABLE 205 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 217 TABLE 206 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 217 TABLE 207 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 218 TABLE 208 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 218 TABLE 209 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 218 TABLE 210 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 219 TABLE 211 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 219 TABLE 212 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 219 TABLE 213 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 220 TABLE 214 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 220 TABLE 215 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 221 TABLE 216 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 217 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 218 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 222 TABLE 219 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 222 TABLE 220 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 222 TABLE 221 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 223 TABLE 222 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 223 TABLE 223 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 224 TABLE 224 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 224 TABLE 225 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 224 TABLE 226 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 225 TABLE 227 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 225 TABLE 228 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 225 TABLE 229 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 226 TABLE 230 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 226 TABLE 231 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 227 TABLE 232 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 227 TABLE 233 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 228 TABLE 234 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 228 TABLE 235 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 228 TABLE 236 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 229 TABLE 237 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 229 TABLE 238 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 230 TABLE 239 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 230 TABLE 240 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 231 TABLE 241 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 231 TABLE 242 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 231 TABLE 243 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 232 TABLE 244 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 232 TABLE 245 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 232 TABLE 246 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 233 TABLE 247 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 233 TABLE 248 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 234 TABLE 249 SAUDI ARABIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 234 TABLE 250 SAUDI ARABIA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 251 SAUDI ARABIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 252 SAUDI ARABIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 235 TABLE 253 SAUDI ARABIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 236 TABLE 254 SAUDI ARABIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 236 TABLE 255 SAUDI ARABIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 237 TABLE 256 SAUDI ARABIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 237 TABLE 257 UAE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 238 TABLE 258 UAE: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 238 TABLE 259 UAE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 238 TABLE 260 UAE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 239 TABLE 261 UAE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 239 TABLE 262 UAE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 239 TABLE 263 UAE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 240 TABLE 264 UAE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 240 TABLE 265 OTHER GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 241 TABLE 266 OTHER GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 267 OTHER GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 268 OTHER GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 242 TABLE 269 OTHER GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 242 TABLE 270 OTHER GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 242 TABLE 271 OTHER GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 243 TABLE 272 OTHER GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 243 TABLE 273 SOUTH AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 244 TABLE 274 SOUTH AFRICA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 275 SOUTH AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 276 SOUTH AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 245 TABLE 277 SOUTH AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 245 TABLE 278 SOUTH AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 245 TABLE 279 SOUTH AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 246 TABLE 280 SOUTH AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 246 TABLE 281 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 247 TABLE 282 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 283 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 284 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 248 TABLE 285 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 248 TABLE 286 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 248 TABLE 287 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 249 TABLE 288 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 249 TABLE 289 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CDSS MARKET, JANUARY 2023– JUNE 2026 251 TABLE 290 CLINICAL DECISION SUPPORT SYSTEM MARKET: DEGREE OF COMPETITION 255 TABLE 291 CDSS MARKET: REGION FOOTPRINT OF KEY PLAYERS 262 TABLE 292 CDSS MARKET: COMPONENT FOOTPRINT 263 TABLE 293 CLINICAL DECISION SUPPORT SYSTEMS MARKET: TYPE FOOTPRINT 264 TABLE 294 CLINICAL DECISION SUPPORT SYSTEMS MARKET: TECHNOLOGY FOOTPRINT 265 TABLE 295 CDSS MARKET: LIST OF STARTUPS/SMES 267 TABLE 296 CDSS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 268 TABLE 297 CLINICAL DECISION SUPPORT SYSTEMS MARKET: PRODUCT LAUNCHES AND UPGRADES (JANUARY 2023–JUNE 2026) 269 TABLE 298 CLINICAL DECISION SUPPORT SYSTEMS MARKET: DEALS (JANUARY 2023–JUNE 2026) 271 TABLE 299 CLINICAL DECISION SUPPORT SYSTEMS MARKET: OTHER DEVELOPMENTS (JANUARY 2023–JUNE 2026) 275 TABLE 300 WOLTERS KLUWER N.V.: BUSINESS OVERVIEW 277 TABLE 301 WOLTERS KLUWER N.V.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 279 TABLE 302 WOLTERS KLUWER N.V.: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023–JUNE 2026 280 TABLE 303 WOLTERS KLUWER N.V.: DEALS, JANUARY 2023–MAY 2026 281 TABLE 304 WOLTERS KLUWER N.V.: OTHER DEVELOPMENTS, JANUARY 2023–JUNE 2026 284 TABLE 305 EPIC SYSTEMS CORPORATION: BUSINESS OVERVIEW 286 TABLE 306 EPIC SYSTEMS CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED 287 TABLE 307 EPIC SYSTEMS CORPORATION: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023– JUNE 2026 289 TABLE 308 EPIC SYSTEMS CORPORATION: DEALS, JANUARY 2023–JUNE 2026 290 TABLE 309 EPIC SYSTEMS CORPORATION: OTHER DEVELOPMENTS, JANUARY 2023–JUNE 2026 291 TABLE 310 ORACLE: BUSINESS OVERVIEW 293 TABLE 311 ORACLE: PRODUCTS/SOLUTIONS/SERVICES OFFERED 294 TABLE 312 ORACLE: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023–JUNE 2026 296 TABLE 313 ORACLE: DEALS, JANUARY 2023–JUNE 2026 297 TABLE 314 MERATIVE: BUSINESS OVERVIEW 300 TABLE 315 MERATIVE: PRODUCTS/SOLUTIONS/SERVICES OFFERED 300 TABLE 316 MERATIVE: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023–MAY 2026 301 TABLE 317 MERATIVE: DEALS, JANUARY 2023–MAY 2026 301 TABLE 318 MERATIVE: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 302 TABLE 319 VERADIGM LLC: BUSINESS OVERVIEW 304 TABLE 320 VERADIGM LLC: PRODUCTS/SOLUTIONS/SERVICES OFFERED 305 TABLE 321 VERADIGM LLC: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023–MAY 2026 307 TABLE 322 VERADIGM LLC: DEALS, JANUARY 2023–MAY 2026 308 TABLE 323 VERADIGM LLC: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 309 TABLE 325 OPTUM, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 312 TABLE 326 OPTUM, INC.: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023–JUNE 2026 313 TABLE 327 OPTUM, INC.: DEALS, JANUARY 2023–MAY 2026 314 TABLE 328 ATHENAHEALTH: BUSINESS OVERVIEW 315 TABLE 329 ATHENAHEALTH: PRODUCTS/SOLUTIONS/SERVICES OFFERED 316 TABLE 330 ATHENAHEALTH: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023–JUNE 2026 316 TABLE 331 ATHENAHEALTH: DEALS, JANUARY 2023–JUNE 2026 317 TABLE 332 ELSEVIER: BUSINESS OVERVIEW 319 TABLE 333 ELSEVIER: PRODUCTS/SOLUTIONS/SERVICES OFFERED 320 TABLE 334 ELSEVIER: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023–JUNE 2026 322 TABLE 335 ELSEVIER: DEALS, JANUARY 2023–JUNE 2026 323 TABLE 336 ZYNX HEALTH, INC.: BUSINESS OVERVIEW 324 TABLE 337 ZYNX HEALTH, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 325 TABLE 338 ZYNX HEALTH, INC.: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023–MAY 2026 326 TABLE 339 ZYNX HEALTH, INC.: DEALS, JANUARY 2023–MAY 2026 326 TABLE 340 ZYNX HEALTH, INC.: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 326 TABLE 341 KONINKLIJKE PHILIPS N.V.: BUSINESS OVERVIEW 327 TABLE 342 KONINKLIJKE PHILIPS N.V.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 328 TABLE 343 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023–JUNE 2026 330 TABLE 344 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023–JUNE 2026 331 TABLE 345 MEDICAL INFORMATION TECHNOLOGY, INC.: BUSINESS OVERVIEW 333 TABLE 346 MEDICAL INFORMATION TECHNOLOGY, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 334 TABLE 347 MEDICAL INFORMATION TECHNOLOGY, INC.: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023–JUNE 2026 335 TABLE 348 MEDICAL INFORMATION TECHNOLOGY, INC.: DEALS, JANUARY 2023–JUNE 2026 336 TABLE 349 MEDICAL INFORMATION TECHNOLOGY, INC.: OTHER DEVELOPMENTS, JANUARY 2023–JUNE 2026 337 TABLE 350 NEXTGEN HEALTHCARE, INC.: BUSINESS OVERVIEW 339 TABLE 351 NEXTGEN HEALTHCARE, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 340 TABLE 352 NEXTGEN HEALTHCARE, INC.: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023–JUNE 2026 341 TABLE 353 NEXTGEN HEALTHCARE, INC.: DEALS, JANUARY 2023–JUNE 2026 342 TABLE 354 CUREMD HEALTHCARE: BUSINESS OVERVIEW 345 TABLE 355 CUREMD HEALTHCARE: PRODUCTS/SOLUTIONS/SERVICES OFFERED 346 TABLE 356 CUREMD HEALTHCARE: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023–JUNE 2026 347 TABLE 357 CUREMD HEALTHCARE: DEALS, JANUARY 2023–JUNE 2026 348 TABLE 358 CUREMD HEALTHCARE: OTHER DEVELOPMENTS, JANUARY 2023–JUNE 2026 348 TABLE 359 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 349 TABLE 360 SIEMENS HEALTHINEERS AG: PRODUCTS/SOLUTIONS/SERVICES OFFERED 350 TABLE 361 SIEMENS HEALTHINEERS AG: PRODUCTS LAUNCHES & UPGRADES, JANUARY 2023–JUNE 2026 352 TABLE 362 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2023–JUNE 2026 352 TABLE 363 EBSCO INFORMATION SERVICES: BUSINESS OVERVIEW 354 TABLE 364 EBSCO INFORMATION SERVICES: PRODUCTS/SOLUTIONS/SERVICES OFFERED 355 TABLE 365 EBSCO INFORMATION SERVICES: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023–JUNE 2026 356 TABLE 366 EBSCO INFORMATION SERVICES: DEALS, JANUARY 2023–JUNE 2026 357 TABLE 367 GE HEALTHCARE: BUSINESS OVERVIEW 358 TABLE 368 GE HEALTHCARE: PRODUCTS/SOLUTIONS/SERVICES OFFERED 360 TABLE 369 GE HEALTHCARE: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023–JUNE 2026 361 TABLE 370 GE HEALTHCARE: DEALS, JANUARY 2023–JUNE 2026 362 TABLE 371 GE HEALTHCARE: OTHER DEVELOPMENTS, JANUARY 2023–JUNE 2026 365 TABLE 372 ECLINICALWORKS, LLC: BUSINESS OVERVIEW 366 TABLE 373 ECLINICALWORKS, LLC: PRODUCTS/SOLUTIONS/SERVICES OFFERED 367 TABLE 374 ECLINICALWORKS, LLC: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023–JUNE 2026 367 TABLE 375 ECLINICALWORKS, LLC: DEALS, JANUARY 2023–JUNE 2026 368 TABLE 376 THE MEDICAL ALGORITHMS COMPANY LIMITED: BUSINESS OVERVIEW 370 TABLE 377 THE MEDICAL ALGORITHMS COMPANY LIMITED: PRODUCTS/SOLUTIONS/SERVICES OFFERED 371 TABLE 378 CARECLOUD, INC.: BUSINESS OVERVIEW 372 TABLE 379 CARECLOUD, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 373 TABLE 380 CARECLOUD, INC.: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023–JUNE 2026 374 TABLE 381 CARECLOUD, INC.: DEALS, JANUARY 2023–JUNE 2026 375 TABLE 382 VISUALDX: BUSINESS OVERVIEW 377 TABLE 383 VISUALDX: PRODUCTS/SOLUTIONS/SERVICES OFFERED 378 TABLE 384 VISUALDX: DEALS, JANUARY 2023–MAY 2026 379 TABLE 385 RISK ASSESSMENT ANALYSIS 398 FIGURE 1 CDSS MARKET SEGMENTATION 35 FIGURE 2 MARKET SCENARIO 40 FIGURE 3 GLOBAL CLINICAL DECISION SUPPORT SYSTEM MARKET, 2024–2031 40 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL DECISION SUPPORT SYSTEM MARKET, 2023–2026 41 FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF CLINICAL DECISION SYSTEM MARKET 42 FIGURE 6 HIGH-GROWTH SEGMENTS IN CLINICAL DECISION SUPPORT SYSTEM MARKET, 2026–2031 43 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN CLINICAL DECISION SUPPORT SYSTEM MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 44 FIGURE 8 INCREASING GOVERNMENT REGULATIONS FOR IMPLEMENTATION OF HCIT SOLUTIONS TO DRIVE MARKET 45 FIGURE 9 SOFTWARE SEGMENT DOMINATED US MARKET IN 2025 46 FIGURE 10 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 46 FIGURE 11 CLINICAL DECISION SUPPORT SYSTEMS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 48 FIGURE 12 CDSS MARKET: PORTER’S FIVE FORCES ANALYSIS 57 FIGURE 13 CLINICAL DECISION SUPPORT SYSTEMS MARKET: VALUE CHAIN ANALYSIS 61 FIGURE 14 CLINICAL DECISION SUPPORT SYSTEM MARKET: ECOSYSTEM ANALYSIS 64 FIGURE 15 INDICATIVE PRICE FOR CDSS MARKET, BY PRODUCT (2025) 66 FIGURE 16 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR CLINICAL DECISION SUPPORT SYSTEMS MARKET 69 FIGURE 17 FIGURE 15 RECENT FUNDING OF SELECTED PLAYERS IN CDSS MARKET 70 FIGURE 18 PATENT PUBLICATION TRENDS IN BIOSIMULATION MARKET, 2015–2026 81 FIGURE 19 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR “CLINICAL DECISION SUPPORT SYSTEMS” PATENTS, 2015–2026 82 FIGURE 20 CLINICAL DECISION SUPPORT SYSTEMS MARKET: TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR PATENTS (JANUARY 2015–JUNE 2026) 84 FIGURE 21 MARKET POTENTIAL OF AI/GEN AI ON CDSS 89 FIGURE 22 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 91 FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 107 FIGURE 24 CLINICAL DECISION SUPPORT SYSTEMS: KEY BUYING CRITERIA, BY COMPONENT 108 FIGURE 25 NORTH AMERICA: CDSS MARKET SNAPSHOT 153 FIGURE 26 ASIA PACIFIC: CDSS MARKET SNAPSHOT 190 FIGURE 27 REVENUE SHARE ANALYSIS OF KEY PLAYERS 253 FIGURE 28 MARKET SHARE ANALYSIS, BY KEY PLAYER (2025) 254 FIGURE 29 CDSS MARKET: BRAND COMPARISON 257 FIGURE 30 EV/EBITDA OF KEY VENDORS 258 FIGURE 31 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF VENDORS 258 FIGURE 32 CLINICAL DECISION SUPPORT SYSTEMS MARKET: KEY PLAYERS, 2025 260 FIGURE 33 CDSS MARKET: COMPANY FOOTPRINT 261 FIGURE 34 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2025) 267 FIGURE 35 WOLTERS KLUWER N.V.: COMPANY SNAPSHOT (2025) 278 FIGURE 36 ORACLE: COMPANY SNAPSHOT (2025) 294 FIGURE 37 VERADIGM LLC: COMPANY SNAPSHOT (2024) 305 FIGURE 38 UNITEDHEALTH GROUP: COMPANY SNAPSHOT (2025) 312 FIGURE 39 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2025) 328 FIGURE 40 NEXTGEN HEALTHCARE, INC.: COMPANY SNAPSHOT (2023) 339 FIGURE 41 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025) 350 FIGURE 42 GE HEALTHCARE: COMPANY SNAPSHOT (2025) 359 FIGURE 43 CARECLOUD, INC.: COMPANY SNAPSHOT (2025) 373 FIGURE 44 RESEARCH DESIGN 383 FIGURE 45 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 388 FIGURE 46 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 390 FIGURE 47 BOTTOM-UP APPROACH 391 FIGURE 48 TOP-DOWN APPROACH 392 FIGURE 49 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 393 FIGURE 50 CLINICAL DECISION SUPPORT SYSTEMS MARKET: CAGR PROJECTION ANALYSIS 393 FIGURE 51 DATA TRIANGULATION METHODOLOGY 396

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們